S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
about
Ion Homeostasis in Rhythmogenesis: The Interplay Between Neurons and AstrogliaSoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's diseaseOn the Relationship between Energy Metabolism, Proteostasis, Aging and Parkinson's Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine.The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory GenesAstrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls.Early activation of microglia and astrocytes in mouse models of spinocerebellar ataxia type 1.S100B blood levels and childhood trauma in adolescent inpatientsStriatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B.S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells.S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal InflammationCombined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease.Retinol (Vitamin A) Increases α-Synuclein, β-Amyloid Peptide, Tau Phosphorylation and RAGE Content in Human SH-SY5Y Neuronal Cell Line.COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progThe role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease.Increased receptor for advanced glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking.In vivo astrocytic Ca(2+) signaling in health and brain disorders.Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes.The role of inflammation in sporadic and familial Parkinson's disease.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Translational potential of astrocytes in brain disorders.Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease.MiR-124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim.Molecular changes in the postmortem parkinsonian brain.l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervationSterile Neuroinflammation and Strategies for Therapeutic InterventionEvaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer's disease.Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's DiseaseReceptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis.Novel interactions of the TRTK12 peptide with S100 protein family members: specificity and thermodynamic characterization.In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinIncreasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.The effects of physical exercise on nonmotor symptoms and on neuroimmune RAGE network in experimental parkinsonism.
P2860
Q26795479-ACBE70ED-228A-4EB5-B9C5-0170DDB90EA8Q27319831-42A204A9-2CB8-4A13-8987-7B5463104196Q28384947-C0364B1C-FE6D-47C4-8E74-7CE5CE75B047Q33714263-CF028795-B515-41E6-BAD3-47EBF71965F9Q33868126-02543B21-3B90-4E39-A618-588EC92D0BC1Q34238909-E944B9DD-2DAF-4313-AE16-0D7386BEF53EQ34864555-F1F3B110-0337-4393-A79F-3640E7C855EFQ35106166-BBE946AA-EFEB-4876-8C0D-BD9B6096D315Q35132340-DCC9C63A-205B-4B51-934C-650C6807B4D5Q35551126-C5D1E5E1-7255-4036-B18C-E4783E80F766Q35673658-D5023FAD-1F46-43BD-B9CF-F1FBB74CA20FQ35681474-C4636808-24B0-45A8-B20D-F2179054B39EQ35708432-BBD94B5A-85EC-4EFE-830C-23B78AF05BD0Q35822548-E1D5CE45-816A-47AD-9C7D-F4FB29F19C81Q35881882-F29C3C57-DA49-416B-97C2-3ED2B3980A27Q36369915-545DEDC8-B568-4302-92A0-6D552A5DDD99Q36616565-AF9C3E78-85CB-464A-A858-7A4DFF46C982Q36630399-113865F5-9BBD-447A-A22B-B21B2B46480AQ37179174-CDF7AC6B-D130-44B1-9744-4ED4C5FD5049Q37414788-33EAE9AB-76C2-4BCF-8D4E-179E845E5015Q37655951-62142ED3-4B6E-4019-A87C-CBDE63C81E31Q38105903-9FB007CE-B30B-4200-ADBF-87A1652758ADQ38541943-156C7C3F-D0DA-4E00-9C3F-E8CE7C38F3F1Q38589482-052C6169-0122-4752-87B1-75A84159E1F9Q38862845-30772CB3-B5E0-4FA9-8E54-190BCE3EDB29Q38874732-1F51606C-C220-412A-B497-A50A802AEFBCQ38887346-F3F498B4-CF8E-4FCA-BA50-D49046607D33Q39012371-5F66ED54-DC69-4012-8BB9-881DBB2B296EQ39018573-4EE1C552-D834-4818-B3B5-0E87B445AD34Q39105980-1490EE8C-EB5A-49D2-A2DB-4E7966FD442EQ39428145-14ECAD20-5694-41E5-AD3A-29D9522EE4E2Q40382235-5A3AC0A7-C67D-4411-8220-6689EE3A6C32Q41376219-BB857EB1-4CF8-430B-8844-01359A340F02Q41871282-95D9B9CE-6681-4641-82CD-F551ACDB73DAQ42128457-17184457-6A0A-4D0A-9662-49B1F723E2E5Q42786914-4FDA958C-A100-4F17-94B2-15672982DB5EQ43162071-156207FE-9BBE-49D7-B81E-910E43BAE62EQ43180542-FB28D92B-94DA-48EF-A78F-6D7D10BD3A5BQ43679571-13AFD5A4-76B6-4FA7-99A2-5592DFFC71FBQ44112559-4FF3D961-AEFC-48FF-818A-BFEA4FE9DA92
P2860
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@ast
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@en
type
label
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@ast
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@en
prefLabel
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@ast
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@en
P2093
P2860
P50
P356
P1433
P1476
S100B is increased in Parkinso ...... gh the RAGE and TNF-α pathway.
@en
P2093
Corina Fleckenstein
Heather L Martin
Johannes D Lang
Kinnari Sathe
Peter Teismann
Ross B Mounsey
Sarah Mustafa
Shigeyoshi Itohara
Zvonimir Vukovic
P2860
P304
P356
10.1093/BRAIN/AWS250
P407
P577
2012-11-01T00:00:00Z